Ten‐Year Cost‐Effectiveness of the Risk Assessment and Management Programme—Diabetes Mellitus ( RAMP ‐ DM ) Relative to Usual Care in Hong Kong Public Primary Care: A Population‐Based Cohort Study
Main finding · Total undiscounted direct medical costs per person, incl. programme costResult — go to the resultDifference US$10 543 lower per personAuthors' conclusion
RAMP-DM was associated with better 10-year clinical outcomes and lower direct medical costs.
Study context
- Population
- Patients with T2D in Hong Kong public primary care, 2009–2019matched cohort
- Participants
- 36,746 patients
- Exposure
- Risk Assessment and Management Programme-Diabetes Mellitus (RAMP-DM) vs usual care
- RAMP-DMn = 18,373
- Usual caren = 18,373reference
- Outcome
- Incremental total direct medical cost per diabetes-related complication avoided
- Follow-up
- 10 years
Methodological detailscost-effectiveness analysis, propensity-score matched, public healthcare provider perspective
- Cost-effectiveness analysis
- Propensity-score matched
- Public healthcare provider perspective
Main finding
As reported in the abstract
Total undiscounted direct medical costs per person, incl. programme cost
Difference
US$10 543 lower per person
By group
RAMP-DM
$23 430
Usual care
US$33 973
- Programme cost per participant
- US$329
Observational data: associations, not effects.
Secondary outcomes
Absolute risk reduction with RAMP-DM · 10 years
- ARR any complications
- 12.1%
- ARR all-cause mortality
- 16.2%
- Based on previously published estimates
Original publication
Ten‐Year Cost‐Effectiveness of the Risk Assessment and Management Programme—Diabetes Mellitus ( RAMP ‐ DM ) Relative to Usual Care in Hong Kong Public Primary Care: A Population‐Based Cohort Study. Diabetes Obes Metab. Published 23 August 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →